Please try another search
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Joanna C. Horobin | 66 | 2019 | Independent Director |
Katherine Rielly-Gauvin | 58 | 2019 | Independent Director |
David Edward Johnson | 38 | 2021 | Independent Director |
Raman Singh | 50 | 2018 | Independent Director |
Martin Leon Lagod | - | - | Board Observer |
Arthur S. Kirsch | 69 | 2016 | Independent Director |
Burton B. Goldstein | 73 | - | Board Observer |
Michael G. Raab | 56 | - | Board Observer |
Stephen M. Bloch | 58 | 2009 | Independent Chairman |
Paul B. Manning | 66 | 2020 | Independent Director |
Roger A. Jeffs | 60 | 2020 | CEO & Director |
Damian deGoa | 43 | 2020 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review